

Medical Treatment for Urological Cancers

Guest Editor:

Dr. Jozefina Casuscelli

1. Department of Urology,
University Hospital of Munich,
81377 Munich, Germany
2. Comprehensive Cancer Center,
University Hospital of Munich,
81377 Munich, Germany

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editor


Dear Colleagues,

The past decade has been characterized by the advent of new therapeutic modalities for the medical treatment of prostate, urothelial and renal cancers. Classic and novel androgen deprivation therapy, cytotoxic chemotherapy, immune checkpoint inhibitors, tyrosine kinase inhibitors and antibody–drug conjugates are now the standard of care for the most common urologic malignancies. Moreover, the treatment paradigm is undergoing a dramatic shift with the advent of the first targeted therapies in uro-oncology, notably PARP and FGFR inhibitors, marking a pivotal moment in the management of these diseases.

This rapidly evolving landscape necessitates the reevaluation of treatment sequencing priorities, and will inevitably result in the phasing out of once-familiar substances from clinical guidelines. The objective of this Special Issue is to navigate the reader through these significant changes, offering insights into the future direction of medical treatment for urological cancers and highlighting the importance of adapting to these new therapeutic opportunities.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)